韦德布什升级评分并提升目标后，Arcus的血量大幅提升。 Arcus stock jumps after Wedbush upgrades rating and raises target.

博公司在股价升级后, 阿克斯生物科学的股票上了5.4%,并将目标价格提高到41美元. Arcus Biosciences shares rose 5.4% after Wedbush upgraded the stock to outperform and raised its price target to $41. 公司在第四季度的收益超出预期, 每股亏损0.89美元,收入为3300万美元. The company beat earnings expectations in the fourth quarter, posting a loss of $0.89 per share on $33 million in revenue. 分析师认为"购买适度",平均目标为30.80美元. Analysts maintain a "moderate buy" rating with an average target of $30.80.